-
Je něco špatně v tomto záznamu ?
Therapeutic Perspectives of 8-Prenylnaringenin, a Potent Phytoestrogen from Hops
K. Štulíková, M. Karabín, J. Nešpor, P. Dostálek,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, přehledy
NLK
Directory of Open Access Journals
od 1997
Free Medical Journals
od 1997
PubMed Central
od 2001
Europe PubMed Central
od 2001
ProQuest Central
od 1997-01-01
Open Access Digital Library
od 1997-01-01
Medline Complete (EBSCOhost)
od 2009-03-01
Health & Medicine (ProQuest)
od 1997-01-01
- MeSH
- flavanony škodlivé účinky chemie farmakologie MeSH
- fytoestrogeny škodlivé účinky chemie farmakologie MeSH
- fytogenní protinádorové látky škodlivé účinky chemie farmakologie MeSH
- Humulus chemie MeSH
- lidé MeSH
- menopauza účinky léků MeSH
- molekulární struktura MeSH
- postmenopauzální osteoporóza farmakoterapie MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Hop (Humulus lupulus L.), as a key ingredient for beer brewing, is also a source of many biologically active molecules. A notable compound, 8-prenylnaringenin (8-PN), structurally belonging to the group of prenylated flavonoids, was shown to be a potent phytoestrogen, and thus, became the topic of active research. Here, we overview the pharmacological properties of 8-PN and its therapeutic opportunities. Due to its estrogenic effects, administration of 8-PN represents a novel therapeutic approach to the treatment of menopausal and post-menopausal symptoms that occur as a consequence of a progressive decline in hormone levels in women. Application of 8-PN in the treatment of menopause has been clinically examined with promising results. Other activities that have already been assessed include the potential to prevent bone-resorption or inhibition of tumor growth. On the other hand, the use of phytoestrogens is frequently questioned regarding possible adverse effects associated with long-term consumption. In conclusion, we emphasize the implications of using 8-PN in future treatments of menopausal and post-menopausal symptoms, including the need for precise evidence and further investigations to define the safety risks related to its therapeutic use.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18033244
- 003
- CZ-PrNML
- 005
- 20181010124956.0
- 007
- ta
- 008
- 181008s2018 sz f 000 00|eng||
- 009
- AR
- 024 7_
- $a 10.3390/molecules23030660 $2 doi
- 035 __
- $a (PubMed)29543713
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Štulíková, Kateřina $u Department of Biotechnology, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic. stulikoa@vscht.cz.
- 245 10
- $a Therapeutic Perspectives of 8-Prenylnaringenin, a Potent Phytoestrogen from Hops / $c K. Štulíková, M. Karabín, J. Nešpor, P. Dostálek,
- 520 9_
- $a Hop (Humulus lupulus L.), as a key ingredient for beer brewing, is also a source of many biologically active molecules. A notable compound, 8-prenylnaringenin (8-PN), structurally belonging to the group of prenylated flavonoids, was shown to be a potent phytoestrogen, and thus, became the topic of active research. Here, we overview the pharmacological properties of 8-PN and its therapeutic opportunities. Due to its estrogenic effects, administration of 8-PN represents a novel therapeutic approach to the treatment of menopausal and post-menopausal symptoms that occur as a consequence of a progressive decline in hormone levels in women. Application of 8-PN in the treatment of menopause has been clinically examined with promising results. Other activities that have already been assessed include the potential to prevent bone-resorption or inhibition of tumor growth. On the other hand, the use of phytoestrogens is frequently questioned regarding possible adverse effects associated with long-term consumption. In conclusion, we emphasize the implications of using 8-PN in future treatments of menopausal and post-menopausal symptoms, including the need for precise evidence and further investigations to define the safety risks related to its therapeutic use.
- 650 _2
- $a fytogenní protinádorové látky $x škodlivé účinky $x chemie $x farmakologie $7 D000972
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a flavanony $x škodlivé účinky $x chemie $x farmakologie $7 D044950
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Humulus $x chemie $7 D027582
- 650 _2
- $a menopauza $x účinky léků $7 D008593
- 650 _2
- $a molekulární struktura $7 D015394
- 650 _2
- $a postmenopauzální osteoporóza $x farmakoterapie $7 D015663
- 650 _2
- $a fytoestrogeny $x škodlivé účinky $x chemie $x farmakologie $7 D048789
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Karabín, Marcel $u Department of Biotechnology, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic. marcel.karabin@vscht.cz.
- 700 1_
- $a Nešpor, Jakub $u Department of Biotechnology, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic. nesporj@vscht.cz.
- 700 1_
- $a Dostálek, Pavel $u Department of Biotechnology, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic. pavel.dostalek@vscht.cz.
- 773 0_
- $w MED00180394 $t Molecules (Basel, Switzerland) $x 1420-3049 $g Roč. 23, č. 3 (2018)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29543713 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20181010125445 $b ABA008
- 999 __
- $a ok $b bmc $g 1340859 $s 1030238
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 23 $c 3 $e 20180315 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
- LZP __
- $a Pubmed-20181008